Literature DB >> 339856

The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR 142,490).

W Peters, R E Howells, J Portus, B L Robinson, S Thomas, D C Warhurst.   

Abstract

Mefloquine (WR 142,490) is a potent blood schizontocide active against drug-sensitive and drug-resistant lines of Plasmodium berghei. The ED50 and ED90 against the P. berghei N strain in albino mice are 1.5 and 3.8 mg/kg respectively. The highly chloroquine-resistant RC line is less sensitive and mefloquine is not fully effective at the maximum tolerated dose in the '4-day test'. Mefloquine has a similar mode of action to quinine both in vitro and (as demonstrated by the morphological changes it induces in P. berghei) in vivo, but is some 100 times more potent. Unlike quinine and WR 122,455 it appears not to interact with DNA. It has no causal prophylactic effect. Mixtures of mefloquine with pyrimethamine, sulphaphenazole or primaquine have an additive effect.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 339856     DOI: 10.1080/00034983.1977.11687206

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  10 in total

1.  Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum.

Authors:  Shu-hua Xiao; Jing-yan Mei; Pei-ying Jiao
Journal:  Parasitol Res       Date:  2010-10-05       Impact factor: 2.289

2.  Antiplasmodial activity of artecyclopentyl mether a new artemisinin derivative and its effect on pathogenesis in Plasmodium yoelii nigeriensis infected mice.

Authors:  Jyoti Agarwal; Suriya Pratap Singh; Debabrata Chanda; Dnyaneshwar Umrao Bawankule; Rajendra Singh Bhakuni; Anirban Pal
Journal:  Parasitol Res       Date:  2011-05-04       Impact factor: 2.289

Review 3.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

4.  Chloroquine resistance in malaria: accessibility of drug receptors to mefloquine.

Authors:  C D Fitch; R L Chan; R Chevli
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

5.  Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses.

Authors:  Yi Tao; Jian Xue; Bin Jiang; Hao-Bing Zhang; Shu-Hua Xiao
Journal:  Parasitol Res       Date:  2015-09-04       Impact factor: 2.289

6.  In vitro and in vivo activities of atalaphillinine and related acridone alkaloids against rodent malaria.

Authors:  H Fujioka; Y Nishiyama; H Furukawa; N Kumada
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 7.  Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification.

Authors:  Protus Arrey Tarkang; Regina Appiah-Opong; Michael F Ofori; Lawrence S Ayong; Alexander K Nyarko
Journal:  Biomark Res       Date:  2016-12-13

8.  Structure-Based Screening of Plasmodium berghei Glutathione S-Transferase Identifies CB-27 as a Novel Antiplasmodial Compound.

Authors:  Emilee E Colón-Lorenzo; Daisy D Colón-López; Joel Vega-Rodríguez; Alice Dupin; David A Fidock; Abel Baerga-Ortiz; José G Ortiz; Jürgen Bosch; Adelfa E Serrano
Journal:  Front Pharmacol       Date:  2020-03-17       Impact factor: 5.810

9.  In vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon.

Authors:  Rafika Zatra; Jean Bernard Lekana-douki; Faustin Lekoulou; Ulrick Bisvigou; Edgard Brice Ngoungou; Fousseyni S Toure Ndouo
Journal:  BMC Infect Dis       Date:  2012-11-15       Impact factor: 3.090

10.  Central role of hemoglobin degradation in mechanisms of action of 4-aminoquinolines, quinoline methanols, and phenanthrene methanols.

Authors:  M Mungthin; P G Bray; R G Ridley; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.